コンテンツへスキップ
Merck

Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.

International journal of clinical oncology (2020-04-12)
Chiyo Nakashima-Nakasuga, Shoichi Hazama, Nobuaki Suzuki, Yuki Nakagami, Ming Xu, Shin Yoshida, Shinobu Tomochika, Nobuyuki Fujiwara, Satoshi Matsukuma, Hiroto Matsui, Yukio Tokumitsu, Shinsuke Kanekiyo, Yoshitaro Shindo, Noriko Maeda, Ryouichi Tsunedomi, Michihisa Iida, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Yoshihiko Hamamoto, Hiroyuki Ogihara, Yoshinobu Hoshii, Hiroaki Nagano
要旨

Colorectal cancer is the third most common cancer worldwide. If biomarkers can be identified in liquid biopsy, diagnosis and treatment can be optimized even when cancerous tissues are not available. The purpose of this study was to identify proteins from liquid biopsy that would be useful as markers of poor prognosis. First, we comprehensively analyzed serum proteins to identify potential biomarkers and focused on serum lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). The relationship between LOX-1 and the prognosis of patients with colorectal cancer has not been reported. Next, we validated this marker using serum samples from 238 patients with colorectal cancer by ELISA and 100 tissue samples by immunohistochemical staining. The optimal cut-off value of serum LOX-1 was 538.7 pg/mL according to time-dependent receiver operating characteristics curve analysis. The overall survival of patients with high levels of serum LOX-1 was significantly poorer than that of individuals with low levels of LOX-1 in the training and test datasets. In multivariate analysis for overall survival, serum LOX-1 was an independent prognostic factor identified in liquid biopsy (hazard ratio = 1.729, p = 0.027). The prognosis of patients with high LOX-1 expression in tumor tissues was significantly poorer than that of individuals with low expression (p =0.047 ). Additionally, inflammatory factors such as white blood cell count, C-reactive protein level, neutrophil/lymphocyte ratio, and monocyte/lymphocyte ratio were significantly higher in the group with high serum LOX-1 levels. Serum LOX-1 might be a useful biomarker of poor prognosis in colorectal cancer.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Mouse Olr1 / Oxidized Low-density Lipoprotein Receptor 1 ELISA Kit